Rapid and validated fluorometric HPLC method for determination of gabapentin in human plasma and urine for clinical application

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 89-94

  Yagi, T ^a   Naito, T ^a   Mino, Y ^a   Takashina, Y ^a   Umemura, K ^a   Kawakami, J ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

fluorometric HPLC; gabapentin; NBD F; pharmacokinetics; plasma; urine

Indexed keywords

BACLOFEN; GABAPEN; GABAPENTIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CALIBRATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; URINARY EXCRETION; VALIDATION PROCESS;

4-CHLORO-7-NITROBENZOFURAZAN; ADULT; AMINES; ANTICONVULSANTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANECARBOXYLIC ACIDS; FLUORESCENT DYES; FLUOROMETRY; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84856331455     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01243.x     Document Type: Article

References (30)

1. McLean MJ,. Gabapentin in the management of convulsive disorders. Epilepsia, 1999; 40: 39-50 discussion S73-74.
2. Bennett MI, Simpson KH,. Gabapentin in the treatment of neuropathic pain. Palliative Medicine, 2004; 18: 5-11. (Pubitemid 38220056)
3. Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E,. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Research, 2001; 47: 229-241. (Pubitemid 34008466)
4. Coderre TJ, Kumar N, Lefebvre CD, Yu JS,. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. Journal of Neurochemistry, 2005; 94: 1131-1139. (Pubitemid 41170599)
5. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN,. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Research, 2000; 40: 123-127. (Pubitemid 30339403)
6. Bahrami G, Mohammadi B,. Sensitive microanalysis of gabapentin by high-performance liquid chromatography in human serum using pre-column derivatization with 4-chloro-7-nitrobenzofurazan: application to a bioequivalence study. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 2006; 837: 24-28. (Pubitemid 43783321)
7. Jalalizadeh H, Souri E, Tehrani MB, Jahangiri A,. Validated HPLC method for the determination of gabapentin in human plasma using pre-column derivatization with 1-fluoro-2,4-dinitrobenzene and its application to a pharmacokinetic study. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 2007; 854: 43-47. (Pubitemid 46962358)
8. Juenke JM, Brown PI, McMillin GA, Urry FM,. Procedure for the monitoring of gabapentin with 2,4,6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection. Clinical Chemistry, 2003; 49: 1198-1201. (Pubitemid 36751114)
9. Hengy H, Kölle EU,. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labelling for ultraviolet detection. The Journal of Chromatography, 1985; 341: 473-478. (Pubitemid 15013697)
10. Sagirli O, Cetin SM, Onal A,. Determination of gabapentin in human plasma and urine by high-performance liquid chromatography with UV-vis detection. Journal of Pharmaceutical and Biomedical Analysis, 2006; 42: 618-624. (Pubitemid 44636091)
11. Chung TC, Tai CT, Wu HL,. Simple and sensitive liquid chromatographic method with fluorimetric detection for the analysis of gabapentin in human plasma. Journal of Chromatography A, 2006; 1119: 294-298.
12. Ratnaraj N, Patsalos PN,. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Therapeutic Drug Monitoring, 1998; 20: 430-434. (Pubitemid 28359994)
13. Jiang Q, Li S,. Rapid high-performance liquid chromatographic determination of serum gabapentin. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 1999; 727: 119-123. (Pubitemid 29189283)
14. Tang PH, Miles MV, Glauser TA, DeGrauw T,. Automated microanalysis of gabapentin in human serum by high-performance liquid chromatography with fluorometric detection. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 1999; 727: 125-129. (Pubitemid 29189284)
15. Chollet DF, Goumaz L, Juliano C, Anderegg G,. Fast isocratic high-performance liquid chromatographic assay method for the simultaneous determination of gabapentin and vigabatrin in human serum. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 2000; 746: 311-314. (Pubitemid 30657948)
16. Gauthier D, Gupta R,. Determination of gabapentin in plasma by liquid chromatography with fluorescence detection after solid-phase extraction with a C18 column. Clinical Chemistry, 2002; 48: 2259-2261. (Pubitemid 35397574)
17. Vermeij TA, Edelbroek PM,. Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 2004; 810: 297-303. (Pubitemid 39243318)
18. Forrest G, Sills GJ, Leach JP, Brodie MJ,. Determination of gabapentin in plasma by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 1996; 681: 421-425. (Pubitemid 26191840)
19. Watanabe Y, Imai K,. High-performance liquid chromatography and sensitive detection of amino acids derivatized with 7-fluoro-4-nitrobenzo-2-oxa-1,3- diazole. Analytical Biochemistry, 1981; 116: 471-472. (Pubitemid 12221217)
20. Hiratsuka T,. Involvement of the 50-kDa peptide of myosin heads in the ATPase activity revealed by fluorescent modification with 4-fluoro-7-nitrobenz- 2-oxa-1,3-diazole. The Journal of Biological Chemistry, 1986; 261: 7294-7299. (Pubitemid 17224727)
21. Center for Drug Evaluation and Research, U.S. Food and Drug Administration (2001) Guidance for Industry Bioanalytical Method Validation. Available at: (accessed 11 March 2010).
22. Backonja M, Glanzman RL,. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clinical Therapeutics, 2003; 25: 81-104. (Pubitemid 36206739)
23. Ettinger AB, Argoff CE,. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics, 2007; 4: 75-83. (Pubitemid 46110806)
24. Evins AE,. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. Journal of Clinical Psychiatry, 2003; 64: 9-14. (Pubitemid 36903902)
25. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache, 2001; 41: 119-128. (Pubitemid 32209899)
26. Mclean MJ,. Clinical pharmacokinetics of gabapentin. Neurology, 1994; 44: S17-S22 discussion S31-32.
27. Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Research, 1998; 31: 91-99. (Pubitemid 28361756)
28. Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC,. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clinical Therapeutics, 2009; 31: 1776-1786.
29. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM,. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. The Journal of Clinical Pharmacology, 2008; 48: 1378-1388.
30. Urban TJ, Brown C, Castro RA, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clinical Pharmacology & Therapeutics, 2008; 83: 416-421. (Pubitemid 351272627)